J&J, Bristol Myers Squibb lose Medicare drug-price talks challenges

Jonathan Raa | Nurphoto | Getty ImagesA federal judge in New Jersey on Monday rejected Johnson & Johnson's and Bristol Myers Squibb's legal challenges to the Biden administration's Medicare drug-price negotiations, ruling that the program is constitutional. The decision is another win for the White House in a bitter legal...

Read more...

FDA approves Pfizer gene therapy Beqvez for treatment of hemophilia B

Pavlo Gonchar | Lightrocket | Getty ImagesThe Food and Drug Administration on Friday approved Pfizer's treatment for a rare genetic bleeding disorder, making it the company's first-ever gene therapy to win clearance in the U.S. The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate...

Read more...

Bristol Myers Squibb (BMY) earnings Q1 2024

The Bristol Myers Squibb research and development center at Cambridge Crossing in Cambridge, Massachusetts, US, on Wednesday, Dec. 27, 2023. Adam Glanzman | Bloomberg | Getty ImagesBristol Myers Squibb on Thursday reported first-quarter revenue that topped expectations as its blockbuster blood thinner Eliquis and several new drugs posted sales growth.But...

Read more...

3.6 million Medicare patients could get heart health coverage

More than 3 million people with Medicare could be eligible for coverage of Wegovy now that the blockbuster weight loss drug is also approved in the U.S. for heart health, according to an analysis released Wednesday by health policy research organization KFF.But some eligible beneficiaries could still face out-of-pocket...

Read more...

Weight loss drug patients spend less on restaurants, takeout: survey

A food delivery messenger carries a take out bag outside aSweetgreen in Manhattan on September 14, 2023.Jeenah Moon | The Washington Post | Getty ImagesA highly popular group of weight loss and diabetes drugs is decreasing some consumers' appetites — and also how much they spend on food.Most people...

Read more...

Eli Lilly weight loss drug Zepbound effective in sleep apnea trials

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, U.S., December 11, 2023. Brendan McDermid | ReutersEli Lilly on Wednesday said its highly popular weight loss drug Zepbound showed the potential to treat patients with the most common sleep-related breathing disorder in two...

Read more...